What is HistoSonics, Inc.'s contact information?

HistoSonics, Inc.'s contact information: info@histosonics.com, inquiries@histosonics.com, +18777400543.

How many employees does HistoSonics, Inc. have?

HistoSonics, Inc. has 300 employees.

What industry does HistoSonics, Inc. belong to?

HistoSonics, Inc. is in the industry of: Medical Devices, Biotechnology, Healthcare.

What are HistoSonics, Inc.'s official social media profiles?

HistoSonics, Inc. Linkedin Page HistoSonics, Inc. Twitter Page

What tech stack does HistoSonics, Inc. use?

Some of the popular technologies that HistoSonics, Inc. uses are: DoubleClick Floodlight, Google Analytics, HubSpot Analytics, WordPress.

What are HistoSonics, Inc.'s office addresses?

HistoSonics, Inc. has 3 known office addresses: 16305 36th Avenue North 300 Plymouth, Minnesota 55446, US 3526 W. Liberty Rd. Ste 100 Ann Arbor, Michigan 48103, US 16305 36th Avenue North, 300, Plymouth, Minnesota 55446, Us.

What is HistoSonics, Inc.'s open headcount?

HistoSonics, Inc. has 9 job postings.

What is the number of ad campaigns for HistoSonics, Inc.?

HistoSonics, Inc. has no advertisements yet.

What is the number of recent news articles about HistoSonics, Inc.?

HistoSonics, Inc. has 5 news articles.

HistoSonics, Inc. - Pubrio Company Profile & Intent

HistoSonics, Inc.

United States · Medical Devices

Medical Devices

Biotechnology

Healthcare

HistoSonics, Inc. is a medical technology company founded in 2009 by scientists from the University of Michigan. The company specializes in histotripsy, a non-thermal therapeutic ultrasound technique that precisely destroys targeted tissue within the body. Their primary product, the "Edison" robotic platform, delivers histotripsy treatments and is particularly effective for non-invasive treatment of liver tumors. Under the leadership of President and CEO Mike Blue, HistoSonics has made significant strategic advancements since 2017, establishing itself as a leader in histotripsy. The company has successfully completed clinical trials, achieving notable outcomes such as 90% local tumor control at 12 months in the HOPE4LIVER trials. HistoSonics also opened a new manufacturing facility in Minneapolis in 2019 and has received multiple innovation awards for its technology. The company aims to make histotripsy a widely accepted treatment option, benefiting both physicians and patients globally.